---
title: Polyaminoacids in drug delivery
description: Explore the role of poly(amino acids) in drug delivery, from nanoparticles and controlled release to gene delivery and smart nanomedicines.
image: https://blog.curapath.com/hubfs/fotos%20blog%20paaa.png
---

[Skip to content](https://blog.curapath.com/polyaminoacids-in-drug-delivery#main-content)

[![White](https://blog.curapath.com/hs-fs/hubfs/White.png?width=553&height=208&name=White.png "White")](https://curapath.com/)

- [Resources](https://resources.curapath.com/en/curapath-resource-library)
- [End to end services](https://curapath.com/end-to-end-services/)
- [Expertise](https://curapath.com/expertise/)
- [Products](https://curapath.com/products)
- [Blog](https://blog.curapath.com)

- [Contact Us](https://curapath.com/contact-us/)

- [Polymers](https://blog.curapath.com/tag/polymers),
- [LNP](https://blog.curapath.com/tag/lnp),
- [PNP](https://blog.curapath.com/tag/pnp)

# Polyaminoacids in drug delivery

![](https://blog.curapath.com/hubfs/fotos%20blog%20paaa.png)

- October 14, 2026

![Miguel Ángel Esteve](https://blog.curapath.com/hubfs/1757332250804.jpg)

[Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve)

From biodegradable carriers to stimuli-responsive and multifunctional nanomedicines, poly(amino acids) are opening new possibilities for the delivery of small molecules, proteins and nucleic acids.

## **Why poly(amino acids) and Why now?**

Drug delivery is moving towards systems that do more than transport a therapeutic molecule. The objective is increasingly to control its stability, biodistribution, cellular uptake and release, while reducing exposure to healthy tissues.

[Poly(amino acids)](https://curapath.com/products/#polyaminoacids) and synthetic polypeptides are particularly attractive in this context because their composition and architecture can be modified to tune properties such as charge, hydrophobicity, biodegradability, self-assembly and responsiveness to biological stimuli.

Poly(amino acids), polypeptides and their derivatives are versatile biodegradable materials that can be used to encapsulate or conjugate a wide range of therapeutic payloads, including small-molecule drugs, nucleic acids, peptides and proteins. Their chemical diversity also enables the development of different delivery architectures, such as nanoparticles, micelles, nanogels and other self-assembled systems. 

The interest in these materials is therefore linked not only to their biodegradability, but to their ability to **combine several functions within a single delivery platform**.

The key question is how this versatility can be translated into more precise and clinically relevant drug delivery systems.

 

## **1. Poly(amino acids) as Versatile Drug Delivery Platforms**

Poly(amino acids) include polymers based on amino-acid-derived building blocks such as glutamic acid, aspartic acid, lysine, histidine or cysteine. By combining different residues and architectures, researchers can modify the [physicochemical properties of the resulting material](https://blog.curapath.com/selecting-the-right-polymer-excipient-for-drug-delivery). This flexibility can be exploited in several ways.

**Hydrophobic segments** can promote self-assembly and facilitate the incorporation of poorly water-soluble drugs. **Charged groups** can interact with nucleic acids or biological membranes. Other functional groups can be used to introduce targeting ligands or stimulus-responsive linkers.

An example is provided by amphiphilic poly(amino acid) nanoparticles developed for antibiotic delivery. In these systems, the balance between hydrophobic and hydrophilic interactions plays an important role in particle formation, while hydrogen bonding can influence nanoparticle morphology and drug-binding capacity.

This highlights an important characteristic of these materials: **polymer structure directly influences delivery performance**.

 

### Encapsulation, conjugation and self-assembly

Poly(amino acids) can be used as drug carriers through different mechanisms:

- **Encapsulation**, in which the drug is incorporated into a nanoparticle or micelle.
- **Covalent conjugation**, in which the therapeutic molecule is linked to the polymer.
- **Electrostatic complexation**, particularly relevant for nucleic acids.
- **Self-assembly**, which enables amphiphilic polymers to form nanoscale structures.

The choice depends on the therapeutic payload and the desired release mechanism.

Biodegradability is another important characteristic, but it needs to be carefully controlled. Degradation that occurs too rapidly may compromise carrier stability, whereas slow degradation may affect clearance.

For this reason, the goal is not simply to develop a biodegradable polymer, but to **control its degradation in relation to drug release and biological activity**.

 

## **2.  From Drug Carriers to Smart Nanomedicines**

One of the most relevant directions in poly(amino acid) [drug delivery](https://blog.curapath.com/polymer-drug-conjugates-explained) is the development of systems that respond to specific characteristics of their biological environment.

### pH and Redox Responsiveness

Changes in pH between the extracellular environment, endosomes and lysosomes can be exploited to modify the ionization, conformation or stability of poly(amino acid)-based carriers. Incorporating pH-sensitive groups can promote structural changes under acidic conditions, facilitating cargo release and, in some cases, endosomal escape.

Redox responsiveness provides a complementary mechanism based on the reducing environment found inside cells. Redox-sensitive bonds, such as disulfide linkages, can undergo cleavage intracellularly, destabilizing the carrier or polymer–drug conjugate and promoting controlled cargo release.

Together, these mechanisms enable poly(amino acid) systems to respond to intracellular conditions and improve the delivery of therapeutic molecules beyond simple accumulation at the target tissue.

### ROS-responsive delivery

Reactive oxygen species (ROS) provide another important endogenous trigger.

Poly(amino acid) nanoparticles incorporating ROS-sensitive chemical groups can undergo structural degradation under oxidative conditions, resulting in controlled drug release. Since oxidative stress is elevated in many pathological conditions, including cancer and inflammatory diseases, these systems offer the possibility of site-selective drug activation.

### From Tissue Targeting to Intracellular Targeting

Drug delivery is increasingly focused on achieving not only tissue selectivity but also cellular and subcellular precision. Reaching the target tissue represents only the first stage; efficient therapy may require uptake by specific cell populations, intracellular trafficking and delivery to a defined organelle or compartment.

For example, poly(amino acid)-based carriers have been engineered to direct therapeutic agents towards mitochondria while incorporating redox-responsive mechanisms for intracellular release. Such multifunctional systems illustrate how targeting, intracellular trafficking and controlled release can be integrated within a single nanomedicine.

However, achieving this level of precision remains a significant challenge. Each additional targeting step introduces new biological barriers and can reduce delivery efficiency. Strategies such as [ligand-mediated targeting](https://blog.curapath.com/functionalized-polymers-in-pharmaceutical-therapies), organelle-specific peptides and stimuli-responsive linkers can help address these barriers, but their effectiveness may vary depending on the therapeutic payload and biological environment.

Therefore, the challenge is not simply to design increasingly sophisticated carriers, but to achieve reliable and reproducible intracellular delivery while maintaining acceptable formulation complexity, stability and manufacturability. This balance remains an important area of development for poly(amino acid)-based nanomedicines.

 

| **Strategy** | **Trigger/ Mechanism** | **Main purpose** | **Typical application** |
| --- | --- | --- | --- |
| **pH-responsive** | Changes in local acidity | Controlled release and/or endosomal escape | Intracellular drug and nucleic acid delivery |
| **Redox-responsive** | Intracellular reducing enviroment | Cleveage of responsive bonds and playload release | Cytosolic delivery |
| **ROS-responsive** | Elevated reactive oxygen species | Disease-site stimulus-triggered release | Cancer and inflammatory diseases |
| **Enzyme-responsive** | Disease- or tissue-associated enzymes | Selective degradation or release | Targeted drug delivery |
| **Cellular targeting** | Ligand-receptor interactions | Preferential uptake by specific cells | Cancer, immune and infectious diseases |
| **Subcellular targeting** | Organelle-specific interactions | Delivery to define intracellular compartments | Mitochondrial or nuclear delivery |

 

### **3. What Can Poly(amino acids) deliver?**

A major advantage of [poly(amino acids)](https://blog.curapath.com/the-next-generation-of-transfection-polymers) is their ability to deliver a wide variety of therapeutic payloads with distinct physicochemical and biological properties. Through appropriate polymer design, these materials can be adapted to transport small molecules, proteins, peptides and nucleic acids while addressing the specific delivery challenges associated with each cargo.

Their tunable composition, charge, hydrophobicity and biodegradability allow the development of delivery systems tailored to improve drug stability, cellular uptake, controlled release and therapeutic efficacy. The main therapeutic payloads and the corresponding roles of poly(amino acids) are summarized below.

| **Therapeutic payload** | **Main delivery challenge** | **Potential role of poly(amino acids)** |
| --- | --- | --- |
| **Small molecules** | Poor solubility, instability or uncontrolled distribution | Encapsulation, conjugation and controlled release |
| **Peptides & proteins** | Degradation and short circulation | Protection, conjugation and sustained delivery |
| **siRNA / mRNA** | Instability, cellular uptake and endosomal escape | Electrostatic complexation and intracellular delivery |
| **DNA / gene editing** | Large size and intracellular barriers | Condensation, protection and endosomal escape |
| **Combination therapies** | Different physicochemical properties | Multicomponent and multifunctional systems |

For small molecules, polymeric nanoparticles can improve aqueous compatibility while enabling sustained and controlled release.

For proteins and peptides, poly(amino acid)-based carriers provide protection against degradation and can prolong circulation time. Similar concepts are also being explored using recombinant polypeptides and engineered protein-based materials.

Nucleic acids present additional challenges because successful delivery requires protection from degradation, efficient cellular uptake, endosomal escape and intracellular release. The tunable charge and side-chain chemistry of poly(amino acids) make them particularly well suited for overcoming these barriers.

 

### **4. Applications of Poly(amino acids) in Drug Delivery**

The versatility of **poly(amino acids)** enables their application across a wide range of therapeutic areas. Their tunable composition, biodegradability and ability to incorporate targeting and stimuli-responsive functions make them suitable for addressing challenges such as poor drug solubility, instability, biological barriers and off-target toxicity. Consequently, these systems are being explored in **cancer therapy, infectious diseases, neurological and inflammatory disorders**, as well as **nucleic acid, peptide and protein delivery**.

### Cancer therapy and inmunotherapy

Cancer remains one of the most extensively studied applications of **poly(amino acid)-based delivery systems**. Their ability to form **nanoparticles, micelles and other nanoscale structures** enables the encapsulation of different therapeutic agents while providing **controlled release and improved drug distribution**.

Stimuli-responsive systems can further exploit characteristics of the **tumour microenvironment**, such as changes in **pH, redox conditions or reactive oxygen species**, to promote drug release at the desired site. Poly(amino acids) are also being explored for **combination therapies** that integrate chemotherapy with immunomodulation or other therapeutic mechanisms. This represents a shift from using polymers simply as carriers towards designing materials that **actively contribute to treatment**.

### Infectious diseases

Poly(amino acids) are also being investigated for [**antimicrobial drug delivery**,](https://blog.curapath.com/antibacterial-polymers-for-medical-devices) particularly in situations where conventional antibiotics have limited access to the site of infection.

Their composition can be adjusted to control **nanoparticle formation, drug loading and release kinetics**. This is particularly relevant for **intracellular infections and antibiotic-resistant bacteria**, where improved cellular uptake and controlled antibiotic release may enhance therapeutic efficacy.

### Neurological and inflammatory diseases

Drug delivery to the nervous system remains challenging because of [biological barriers](https://curapath.com/targeted-lipid-nanoparticles/) such as the **blood–brain barrier**. Poly(amino acid)-based nanoparticles and nanogels can be engineered to improve **drug stability, circulation and localized release**.

**Stimuli-responsive systems** are particularly interesting for inflammatory and neurological disorders because pathological environments can provide endogenous triggers for drug release. This approach may increase drug exposure at the affected site while **reducing systemic toxicity**.

### Gene and protein delivery

Poly(amino acids) are also promising carriers for **biological macromolecules**, including peptides, proteins and nucleic acids. Their **tunable charge and side-chain chemistry** allow them to interact with and protect sensitive molecules while facilitating cellular uptake.

For nucleic acids, these systems can be designed to address several barriers simultaneously, including **degradation, cellular internalization and endosomal escape**. Similar principles can be applied to protein and peptide delivery, where **protection and controlled release** are essential for maintaining biological activity.

Overall, these applications highlight the broad potential of **poly(amino acids) as adaptable drug delivery platforms**. Their ability to combine **biodegradability, targeting and stimulus responsiveness** provides opportunities to design increasingly **precise and multifunctional therapeutic systems**.

 

### 5. From Promising Nanoparticles to Real Medicines: Challenges and Opportunities

The increasing sophistication of **poly(amino acid)-based nanomedicines** does not eliminate the major challenges associated with their translation into **clinically relevant products**. Demonstrating promising results in laboratory models is only one step in the development process. These systems must also show **predictable behaviour in complex biological environments**, consistent performance between batches and compatibility with[**scalable manufacturing processes**](https://curapath.com/end-to-end-services/).

### Biological Complexity

Nanoparticle behaviour depends on numerous biological variables, including **particle size, surface chemistry, protein corona formation, tissue architecture, immune interactions and disease heterogeneity**. These factors can influence circulation time, biodistribution, cellular uptake, drug release and clearance, making it difficult to predict how a formulation will perform in patients.

A representative example is the **enhanced permeability and retention (EPR) effect**. Although it has provided an important conceptual framework for tumour targeting, its magnitude can vary considerably between tumour types, patients and experimental models. Consequently, relying on passive accumulation alone may not provide sufficient targeting precision. Combining passive delivery with **active targeting or stimuli-responsive mechanisms** may help improve selectivity, but also adds further complexity to the formulation.

### Reproducibility and Manufacturing

Successful clinical translation requires rigorous control over multiple formulation and material parameters, including:

- **Molecular weight and molecular weight distribution**
- **Polymer composition and sequence**
- **Degree of functionalization**
- **Particle size and polydispersity**
- **Drug loading efficiency**
- **Surface characteristics**
- **Drug release profile**
- **Polymer degradation and stability**

These characteristics can directly influence **nanoparticle formation, biological interactions and therapeutic performance**. Even relatively small variations between batches may affect the final product, making **robust [analytical methods](https://blog.curapath.com/advanced-analytical-characterization-of-polymeric-excipients) and well-controlled manufacturing processes** essential.

Scaling poly(amino acid)-based systems from laboratory formulations to **reproducible, scalable and [GMP](https://blog.curapath.com/when-does-a-polymer-need-to-be-gmp-grade)-compatible manufacturing** therefore remains a significant challenge. The synthetic process, purification, formulation and final product characteristics all need to be sufficiently controlled to ensure consistent quality and performance.

### Complexity versus Therapeutic Value

Multifunctional delivery systems can address several biological barriers simultaneously by combining **targeting, controlled release and stimulus-responsive mechanisms**. However, each additional component introduces another variable to control and can increase manufacturing complexity, production costs and regulatory requirements.

The goal is therefore not necessarily to develop the most complex system, but to identify the **simplest formulation capable of providing a meaningful therapeutic advantage**. Future progress will depend on finding the right balance between **biological functionality, [reproducibility, scalability and manufacturability](https://resources.curapath.com/cdmo-services-brochure)**.

Ultimately, successful poly(amino acid) nanomedicines will need to combine **well-defined materials and predictable biological behaviour** with robust manufacturing processes. Addressing these challenges will be essential for moving poly(amino acid)-based delivery systems from promising experimental platforms towards **clinically relevant drug delivery technologies**.

---

### 6. What's Next for Poly(amino acids) in Drug Delivery?

The field is moving towards increasingly precise control over both **material properties and therapeutic performance**. Three major directions are emerging.

The first is **intracellular and subcellular targeting**, where delivery systems are engineered to reach specific organelles such as mitochondria rather than targeting tissues alone.

The second involves **multifunctional and hybrid nanomedicines**, in which poly(amino acids) are combined with complementary materials to integrate multiple therapeutic functions, including imaging, phototherapy and immunotherapy.

The third focuses on **rational material design**. Given the enormous number of possible polymer compositions and architectures, establishing robust **structure–property–function relationships** has become increasingly important. Computational modelling, high-throughput screening and **artificial intelligence** are expected to accelerate the identification of optimized materials.

Ultimately, the successful translation of poly(amino acid)-based drug delivery systems will depend not only on achieving sophisticated biological performance but also on developing **well-defined materials, reproducible manufacturing processes** and a clear relationship between formulation characteristics and therapeutic outcomes.

---

##### Conclusion

Poly(amino acids) offer a **versatile platform for the development of next-generation drug delivery systems**.

Their combination of **biodegradability, chemical flexibility, self-assembly and tunable biological interactions** enables applications ranging from small-molecule delivery to proteins, nucleic acids and combination therapies.

The field is also moving towards increasingly sophisticated systems capable of responding to **biological stimuli and targeting specific cellular environments**.

The key challenge now is translating this molecular versatility into formulations that are not only biologically effective, but also **reproducible, scalable and suitable for clinical development**.

Poly(amino acids) may therefore have an important role in the transition from conventional drug carriers towards **more precise and programmable drug delivery platforms**.

At [Curapath](https://curapath.com/), we support the development of advanced **poly(amino acid)-based drug delivery systems**, from early formulation and process development through scale-up and GMP manufacturing. Our expertise in polymer-based delivery platforms enables us to develop and optimize systems tailored to different therapeutic payloads, with a focus on **controlled release, biological performance, scalability and clinical translation**.

#### Looking to explore whether poly(amino acids)<https://curapath.com/end-to-end-services/#info> could be the right delivery platform for your therapeutic payload? [Get in touch](https://curapath.com/contact-us/) with our team to discuss your drug delivery strategy and identify the most suitable approach for your program.

 

 

 

 Blog Post

## Related Articles

Want to know more about this NanoWorld? Check the other entries of NanoTalks, Curapath magazine about latests trends and practices.

[Check all articles](https://blog.curapath.com)

 Contact Us

### Reach out to our team

Do you have a project you want to discuss with our team? Do you want to know more about our capabilities and services? Don't hesitate and get in touch with us today.

[Contact Us](https://resources.curapath.com/en/curapath-contact-us)

 Keep updated

### Subscribe to NanoTalks

Keep up to date with the latest news in the field of non-viral vectors and nanobiotechnology.

[![Inverted](https://blog.curapath.com/hs-fs/hubfs/Inverted.png?width=300&height=113&name=Inverted.png "Inverted")](https://curapath.com/)

Toggle

1. [About](https://curapath.com/about-us/)
2. [End-To-End Services](https://curapath.com/end-to-end-services/)
3. [Expertise](https://curapath.com/expertise/)
4. [News & Resources](https://curapath.com/news-events/)
5. [Contact Us](https://curapath.com/contact-us/)

---

[Follow us on LinkedIn](https://www.linkedin.com/company/polypeptide-therapeutic-solutions/mycompany/) [Follow us on Twitter](https://curapath.wpengine.com/)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Miguel Ángel Esteve",
    "url" : "https://blog.curapath.com/author/miguel-ángel-esteve"
  },
  "dateModified" : "2026-10-14T12:37:33.133Z",
  "datePublished" : "2026-10-14T12:37:33.000Z",
  "headline" : "Polyaminoacids in drug delivery",
  "image" : [ "https://blog.curapath.com/hubfs/fotos%20blog%20paaa.png" ],
  "mainEntityOfPage" : {
    "@id" : "https://blog.curapath.com/polyaminoacids-in-drug-delivery",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://blog.curapath.com/hubfs/curapath_logo_full_color_rgb_552.6304px@72ppi.png"
    },
    "name" : "Curapath"
  }
}
```